[O-31] 一般演題口演セッション31
治療創薬・再生医療１ E

[O-31-9] Pooled analysis from the SAkura trials with satralizumab in neuromyelitis optica spectrum disorder

^○Jerome De Seze¹, Brian G. Weinshenker², Yusuke Terada³, Yuichi Kawata³, Athos Gianella-borradori⁴, H.-christian Von Büdingen⁵, Gaelle Klingelschmitt⁵, Anthony Traboulsee⁶, Takashi Yamamura⁷ (1.Hôpital de Hautepierre, 2.Mayo Clinic, 3.Chugai Pharmaceutical Co., Ltd, Tokyo, 4.Chugai Pharma USA LLC, 5.F. Hoffmann-La Roche Ltd, 6.University of British Columbia, 7.National Center of Neurology and Psychiatry)